Stocks
News
ETFs
Economy
Currencies
Press Releases
Vir Biotechnology, Inc. - Common Stock (VIR)
Last Price
6.5800
Change
+0.0800 (1.23%)
NASDAQ
· Last Trade: Dec 8th, 7:17 PM EST
Quote
News
Press Releases
Chart
Historical
FAQ
About
Competitors
Is Alnylam Pharmaceuticals a Millionaire Maker?
fool.com
This hot biotech stock could have a lot more room to run.
Via
The Motley Fool
· December 7, 2025
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown
stocktwits.com
Via
Stocktwits
· November 9, 2025
Earnings Scheduled For November 5, 2025
benzinga.com
Via
Benzinga
· November 5, 2025
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
benzinga.com
Via
Benzinga
· August 29, 2025
This Southwest Gas Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday
benzinga.com
Via
Benzinga
· August 29, 2025
Earnings Scheduled For August 6, 2025
benzinga.com
Via
Benzinga
· August 6, 2025
Earnings Scheduled For May 7, 2025
benzinga.com
Via
Benzinga
· May 7, 2025
Earnings Outlook For Vir Biotechnology
benzinga.com
Via
Benzinga
· May 6, 2025
5 Analysts Have This To Say About Vir Biotechnology
benzinga.com
Via
Benzinga
· April 17, 2025
7 Analysts Have This To Say About Vir Biotechnology
benzinga.com
Via
Benzinga
· February 28, 2025
This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
benzinga.com
Via
Benzinga
· August 28, 2025
This Guess Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
benzinga.com
Via
Benzinga
· August 28, 2025
This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
benzinga.com
Via
Benzinga
· August 27, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
Via
Benzinga
· August 27, 2025
Earnings Scheduled For February 26, 2025
benzinga.com
Via
Benzinga
· February 26, 2025
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment
investors.com
The company is working to engage the immune system to attack cancer cells.
Via
Investor's Business Daily
· January 8, 2025
Vir (VIR) Q2 Revenue Drops 61%
fool.com
Via
The Motley Fool
· August 7, 2025
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
Via
Benzinga
· July 11, 2025
Where Vir Biotechnology Stands With Analysts
benzinga.com
Via
Benzinga
· July 11, 2025
Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
benzinga.com
Via
Benzinga
· May 22, 2025
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
benzinga.com
Via
Benzinga
· May 12, 2025
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
benzinga.com
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.
Via
Benzinga
· January 10, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
Via
Benzinga
· January 8, 2025
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
benzinga.com
Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies.
Via
Benzinga
· January 8, 2025
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Via
Benzinga
· January 8, 2025
